Diabetes Archives

Latest Posts

cytotools medday stock black friday drop phase III fail

News and Trends 4 Dec 2015

Black Friday Ruin as TWO Biotechs Fail in Phase III Trials

A shocking Black Friday for these two Biotechs: Both CytoTools (Germany) and MedDay (France) phase III trials in chronic disease flopped massively, and stocks dropped as much as 85% in…

December 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

Ablynx – the Belgian Nanobody biotech (which uses monoclonal antibodies of Alpacas) has entered a new and exclusive partnership with the Danish Novo Nordisk on a mysterious disease... Ablynx are…

November 26, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 12 Oct 2015

A Sweet idea from Napoli; An Italian start-up will renovate the Artificial Sweetener market

Monellin chain B is an artificial sweetener initially mistaken for a carbohydrate. It has since been established to actually be a natural protein based sweetner which is fairly unstable. iSweetch…

October 12, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 18 Sep 2015

Servier to revolutionize Diabetes treatment thanks to Intarcia’s successful Phase III

Treatment of diabetes hasn't changed so much since the development of first human insulin by Genentech. But Boston-based Intarcia (a partner of Servier and one of the 9 billion-dollar Biotech…

September 18, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 16 Sep 2015

Giving new life to Sanofi’s annual €6.2Bn diabetes blockbuster Lantus

Sanofi has announced positive results of its combination drug LixiLan phase III trials for Type 2 diabetes. Constituted from both Lixisenatide and insulin glargine Lantus, LixiLan is developed to tackle…

September 16, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Sep 2015

Genkyotex’ NOX inhibitor candidate Fails to follow through on Phase II

The French biotech Genkyotex has announced Phase II results for GKT137831 in diabetic kidney disease. The NOX1-4 inhibitor failed to reduce albuminuria. Genkyotex focuses on developing inhibitors of nicotinamide adenine…

September 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 4 Sep 2015

Gut bacteria growth time can cause disease?

A method of profiling bacterial growth time in the gut's microbiome has been shown to be a rudimentary diagnostic tool for IBS and diabetes type II. A research team came…

September 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 2 Sep 2015

Novo-expansion! US Based Calibrium and MB2 snapped up by Danish Diabetes Giant

Novo Nordisk has acquired two small Indiana based research Biotechs, Calibrium and MB2, as part of its strategy to establish itself in the US as a major Diabetes research giant.…

September 2, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 3 Aug 2015

Sanofi’s CEO, Olivier Brandicourt takes stock of its Biotech pipeline

Olivier Brandicourt, new CEO of Sanofi since last April, has been interviewed by EuroBusiness Media on the company's last results. The successor of Chris Viehbacher took the opportunity to show the…

August 3, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 1 Jul 2015

Is Adocia & Eli Lilly’s treatment the new diabetes blockbuster?

Adocia and Eli Lilly completed an impressive Phase Ib clinical trial evaluating BioChaperone Lispro, a treatment designed to accelerate insulin absorption. The study aimed to compare BioChaperone Lispro to Lilly’s…

July 1, 2015 - 2 minutesmins - By Lourdes Riquelme

diabetes type 2 sanofi novo nordisk eli lilly

News and Trends 11 Jun 2015

Pharmas step on the gas chasing the next blockbuster in Type 2 Diabetes

Hundreds of millions of people all over the word suffer from type 2 Diabetes and the competition between pharma companies is fierce. Amongst them, Sanofi must think that good things…

June 11, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 29 May 2015

Poxel is Looking towards Japan’s Lucrative Diabetes Market

Poxel, the French company that made a €27M IPO last February, announced the successful conclusion of a phase 1 clinical trial in Japanese subjects with Imeglimin, its lead drug candidate.…

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering